GMMG multiple myeloma long-term follow-up registry

National, Observational, Non-interventional, Retro- and Prospective Clinical Multiple Myeloma Registry GMMG

This registry collects long-term health and survival information from people with multiple myeloma who previously took part in a GMMG therapy study.

Quick facts

• Study type: Observational
• Enrollment: 999 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University of Heidelberg Medical Center (other)
• Drugs / interventions: elotuzumab
• Locations: 35 sites (Berlin and 34 other locations)
• Trial ID: NCT07111884 on ClinicalTrials.gov

What this trial studies

The GMMG registry is a national, non-interventional database that combines retrospective and prospective clinical data from patients enrolled in GMMG-led therapy trials across Germany. It links trial databases with ongoing follow-up information to capture outcomes such as overall survival, progression-free survival, cause of death and therapy-free intervals after first relapse. Data are pseudonymized and entered into an electronic case report form with follow-up visits every six months until first progression and annually thereafter. The registry was activated in December 2022 and currently includes data from 35 participating GMMG centers, with no fixed sample size limit.

Who should consider this trial

Good fit: People with multiple myeloma who previously participated in a therapy study conducted by the GMMG and do not have organ amyloidosis at diagnosis are ideal candidates.

Not a fit: Patients who never participated in a GMMG therapy study or who had organ amyloidosis at diagnosis are not eligible and are unlikely to benefit from inclusion in this registry.

Why it matters

Potential benefit: If successful, the registry could improve understanding of long-term outcomes and real-world treatment effects in multiple myeloma, helping clinicians and researchers make better care and study-design decisions.

How similar studies have performed: Other national and disease-specific registries have successfully provided real-world evidence on long-term outcomes and safety in multiple myeloma, so this approach is established rather than novel.

Eligibility criteria

Inclusion Criteria:

* Previous participation in a a therapy study of the GMMG study group

Exclusion Criteria:

* patients with organ amyloidosis at time of diagnosis

Where this trial is running

Berlin and 34 other locations

• HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie — Berlin, Germany (RECRUITING)
• Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie) — Berlin, Germany (RECRUITING)
• Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin — Bielefeld, Germany (RECRUITING)
• Medizinische Universitätsklinik, Knappschaftskrankenhaus — Bochum, Germany (RECRUITING)
• Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie — Bonn, Germany (RECRUITING)
• Klinikum Chemnitz GmbH, Innere Medizin III — Chemnitz, Germany (RECRUITING)
• Universitätsklinikum Köln, Klinik I - Innere Medizin — Cologne, Germany (RECRUITING)
• Onkologisches Studienzentrum Darmstadt — Darmstadt, Germany (RECRUITING)
• Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie — Darmstadt, Germany (RECRUITING)
• Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie — Düsseldorf, Germany (RECRUITING)
• Universitätsklinik Erlangen — Erlangen, Germany (RECRUITING)
• Universitätsklinikum Essen, Klinik für Hämatologie und Stammzelltransplantation — Essen, Germany (RECRUITING)
• Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation — Essen, Germany (RECRUITING)
• Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II — Frankfurt am Main, Germany (RECRUITING)
• Justus-Liebig-Universität, Medizinische Klinik IV — Giessen, Germany (RECRUITING)
• Kath. Krankenhaus Hagen GmbH, Abt. Hämatologie/Onkologie — Hagen, Germany (RECRUITING)
• Asklepios Klinik Hamburg Altona, II. Med. Klinik — Hamburg, Germany (RECRUITING)
• Onkologische Schwerpunktpraxis — Heidelberg, Germany (RECRUITING)
• University Hospital Heidelberg, Med. Klinik V — Heidelberg, Germany (RECRUITING)
• SLK Kliniken Heilbronn, Med. Klinik III — Heilbronn, Germany (RECRUITING)
• Universitätsklinikum des Saarlandes, Innere Medizin I — Homburg, Germany (RECRUITING)
• Westpfalz-Klinikum GmbH — Kaiserslautern, Germany (RECRUITING)
• Praxisklinik für Hämatologie und Onkologie — Koblenz, Germany (RECRUITING)
• Onkologisches Zentrum, Gemeinschaftspraxis f. Hämatologie u. Onkologie im Caritas KH — Lebach, Germany (RECRUITING)
• Universitätsmedizin der Johannes Gutenberg-Universität Mainz, III. Med. Klinik — Mainz, Germany (RECRUITING)
• III. Medizinische Klinik Hämatologie und Internistische Onkologie — Mannheim, Germany (RECRUITING)
• Mannheimer Onkologie Praxis — Mannheim, Germany (RECRUITING)
• Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie — Marburg, Germany (RECRUITING)
• Krankenhaus Maria Hilf GmbH, Franziskuskrankenhaus, Med. Klinik I — Mönchengladbach, Germany (RECRUITING)
• Krankenhaus Barmherzige Brüder, Klinik für Onkologie und Hämatologie — Regensburg, Germany (RECRUITING)
• Diakonie-Klinikum Schwäbisch Hall gGmbH, Innere Medizin III — Schwäbisch Hall, Germany (RECRUITING)
• ZAHO-Zentrum für ambulante Hämatologie und Onkologie, Standort Siegburg — Siegburg, Germany (RECRUITING)
• Diakonissen-Stiftungs-Krankenhaus Speyer — Speyer, Germany (RECRUITING)
• Klinikum Mutterhaus der Borromäerinnen gGmbH — Trier, Germany (RECRUITING)
• University Hospital Tübingen, Med. Klinik und Poliklinik, Abt. II — Tübingen, Germany (RECRUITING)

Study contacts

• Principal investigator: Hartmut Goldschmidt, Prof. — University Hospital Heidelberg
• Study coordinator: Eileen Kurre

Conditions: Multiple Myeloma, registry, longtime follow-up, elotuzumab, real world data